Long-acting antipsychotics: is what we know really so? - Authors' reply

Taishiro Kishimoto¹, Katsuhiko Hagi², Shunya Kurokawa³, John M Kane⁴, Christoph U Correll⁵

Affiliations

¹ Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, New York, NY, USA; Department of Psychiatry and Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA. Electronic address: tkishimoto@keio.jp.
² Sumitomo Dainippon Pharma, Tokyo, Japan.
³ Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan.
⁴ Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, New York, NY, USA; Department of Psychiatry and Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA.
⁵ Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, New York, NY, USA; Department of Psychiatry and Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.

PMID: 34303403
DOI: 10.1016/S2215-0366(21)00249-2

Comment

Long-acting antipsychotics: is what we know really so? - Authors' reply

Taishiro Kishimoto et al. Lancet Psychiatry. 2021 Aug.

. 2021 Aug;8(8):651-652.

doi: 10.1016/S2215-0366(21)00249-2.

Authors

Taishiro Kishimoto¹, Katsuhiko Hagi², Shunya Kurokawa³, John M Kane⁴, Christoph U Correll⁵

Affiliations

¹ Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, New York, NY, USA; Department of Psychiatry and Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA. Electronic address: tkishimoto@keio.jp.
² Sumitomo Dainippon Pharma, Tokyo, Japan.
³ Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan.
⁴ Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, New York, NY, USA; Department of Psychiatry and Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA.
⁵ Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, New York, NY, USA; Department of Psychiatry and Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.

PMID: 34303403
DOI: 10.1016/S2215-0366(21)00249-2

No abstract available

PubMed Disclaimer

Conflict of interest statement

TK reports personal fees from Banyu, Eli Lilly, Janssen, Kyowa Pharmaceutical Industry, Lundbeck, Novartis, Otsuka, Sumitomo Dainippon, and Takeda; and grants from Sumitomo Dainippon and Otsuka. KH is an employee of Sumitomo Dainippon Pharma. SK reports personal fees from Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, and Mochida Pharmaceutical. JMK reports personal fees from Alkermes, Acadia, Dainippon Sumitmo, Intracellular Therapies, Merck, Neurocrine, Reviva, Roche, Saladex, Sunovion, Takeda, Teva, and LB Pharma; and grants and personal fees from H Lundbeck, Janssen, and Otsuka. JMK is also a shareholder of LB Pharma and The Vanguard Research Group. CUC reports personal fees from Acadia, Alkermes, Allergan, Angelini, Axsome, Bristol-Myers Squibb, Gedeon Richter, IntraCellular Therapies, Janssen (Johnson & Johnson), Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva; and royalties from UpToDate. CUC is also a stock option holder of LB Pharma. TK and KH contributed equally to this Correspondence.

Comment on

Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Kishimoto T, et al. Lancet Psychiatry. 2021 May;8(5):387-404. doi: 10.1016/S2215-0366(21)00039-0. Epub 2021 Apr 13. Lancet Psychiatry. 2021. PMID: 33862018
Long-acting antipsychotics: is what we know really so?
Cosgrove L, Mintzes B, Bursztajn HJ, Shaughnessy AF. Cosgrove L, et al. Lancet Psychiatry. 2021 Aug;8(8):651. doi: 10.1016/S2215-0366(21)00237-6. Lancet Psychiatry. 2021. PMID: 34303402 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Long-acting antipsychotics: is what we know really so? - Authors' reply

Affiliations

Long-acting antipsychotics: is what we know really so? - Authors' reply

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical